Navigation Links
VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ
Date:4/3/2009

SAN FRANCISCO, April 3 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that it has received a letter, dated March 31, 2009, from the staff of the NASDAQ Stock Market informing the Company that it does not currently comply with NASDAQ Marketplace Rule 4310(c)(3). NASDAQ Marketplace Rule 4310(c)(3) requires companies maintain either: (i) $2,500,000 in stockholders' equity; (ii) a market value of listed securities of $35,000,000; or (iii) net income from continuing operations of $500,000 in the most recently completed fiscal year or two of the last three most recently completed fiscal years. The Company intends to submit a specific plan to achieve and sustain compliance with the $2,500,000 stockholders' equity standard by April 15, 2009, including the time frame for completion of the compliance plan. If the NASDAQ staff determines that the Company's plan does not adequately address the issue noted above, the NASDAQ staff will provide written notice that the Company's securities will be delisted. At that time, the Company may appeal the NASDAQ staff's determination to a NASDAQ Listing Qualifications Panel (the "Panel"), which would stay any further delisting action by NASDAQ pending a final decision by the Panel. No assurances can be provided that NASDAQ will grant the Company sufficient time to execute its plan to insure that it will maintain its NASDAQ listing.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candidate, VIA-2291, targets a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Savient Pharmaceuticals to Raise $31 Million Through Registered Direct Offering
2. Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
3. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
4. NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
5. Alseres Pharmaceuticals, Inc. Complies with NASDAQ Rule Regarding Recently Filed 10-K
6. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
7. VIA Pharmaceuticals to Present Poster at AHA Arteriosclerosis, Thrombosis and Vascular Biology Conference 2009
8. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
9. Peregrine Pharmaceuticals Awarded New U.S. Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio
10. Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors
11. VIA Pharmaceuticals Complies With NASDAQ Rules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Inflamax scientists worked closely with internationally ... the study, which will provide critical insight into ... in the study of allergy treatments, the Environmental ... models. Although both the models are well recognized ... direct comparison between the allergic responses evoked by ...
(Date:5/21/2013)... 21, 2013 PathoGenetix, Inc., a commercial-stage ... typing, announced today that it has successfully identified and ... strains obtained from the Centers for Disease Control and ... technology. The findings are detailed in a poster ... Society for Microbiology in Denver on Monday. , The ...
(Date:5/20/2013)... (PRWEB) May 21, 2013 Grace ... specializing in “game-changing” life science and health related private ... Dergham to its International Project Team. Dergham's expertise in ... greater multi-cultural depth to Grace Century as it continues ... globe. , Ms. Dergham holds both an under graduate ...
(Date:5/20/2013)... Calif. , May 20, 2013  (PSHR) ... providing naturally based products across a broad range ... company has retained investor relations firm, BlueWater Advisory ... the return to trading process, and to direct ... trading initiation. Matthew Mills ...
Breaking Biology Technology:Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 2New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 3Dalia Dergham Joins Grace Century FZ LLC International Project Team 2Pacific Shore Holdings Retains Investor Relations Firm 2
... Aug. 23 Monogram,Biosciences, Inc. (Nasdaq: MGRM ) ... scheduled to present a corporate overview at the Thomas,Weisel ... 3:15 p.m. (Eastern Time) at the Four Seasons Hotel ... or the subsequent archived,recording, log on to http://www.monogrambio.com ...
... Conn., Aug. 22 Biodel, Inc. (Nasdaq:,BIOD) ... M.D., to its,Scientific Advisory Board (SAB). ... President of Research,and Development at Kos Pharmaceuticals, ... until Kos was acquired by Abbott Laboratories. ...
... ZymoGenetics, Inc. (Nasdaq:,ZGEN) announced that the company ... update on the regulatory review of recombinant thrombin,(rThrombin). ... on August 22 at 5:00,p.m. Eastern Time by ... the call approximately 10 minutes prior to,the scheduled ...
Cached Biology Technology:Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007 2Ralf Rosskamp, M.D. Joins Biodel's Scientific Advisory Board 2Ralf Rosskamp, M.D. Joins Biodel's Scientific Advisory Board 3ZymoGenetics Will Hold Conference Call Today at 5:00 p.m. Eastern Time to Provide Update on rThrombin 2
(Date:5/21/2013)... in shape is an uphill battle? Try staying fit ... weightlessness withers muscle and bone. , That,s the challenge ... with a new three-year, $1.2 million grant from NASA. ... during multiyear exploratory missions. , "You could give astronauts ... can,t get them to stick to it, it isn,t ...
(Date:5/21/2013)... Where? Copenhagen, Denmark: Bella Center Congress Centre ... , Why? An annual meeting focusing ... manufacturing and installation, drawing on leading experiences from all ... from a record of more than 900 abstracts received ... and oral presentations, more than 460 visual presentation, 55 ...
(Date:5/21/2013)... way genes function without changing the underlying DNA ... of pregnant women during any trimester, potentially providing ... weeks after giving birth, and an opportunity to ... of the small study involving 52 pregnant women ... Psychiatry . , "Postpartum depression can be harmful ...
Breaking Biology News(10 mins):Fueling fitness on the final frontier 221st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3
... Fish become feisty but fearful when facing themselves in ... like something they don,t understand," said Julie Desjardins, a post-doctoral ... be published in Biology Letters describing the study. ... is just so far outside their realm of experience that ...
... of life" has been constructed by researchers at ... for the gamma-proteobacteria, a large group of medically ... Salmonella typhimurium, and other disease-causing organisms.* By building ... identify similarities and differences between the make-up of ...
... A research collaboration lead by a professor from ... work to develop methods to protect agriculturally important crops ... with the support of a $1.45 million award from ... sponsored by the National Science Foundation (NSF) and the ...
Cached Biology News:Fish facing reflections become feisty but fearful 2Fish facing reflections become feisty but fearful 3New 'Tree of Life' established for one of the largest groups of bacteria 2New 'Tree of Life' established for one of the largest groups of bacteria 3Plant protection research targets cacao in developing countries 2
... For use as a carrier ... precipitation. Physical form: Solution in ... 7.4, 1 mM EDTA Preparation ... Concentration: 10 ...
... Genome ChIP-on-chip Microarray is specifically designed ... cerevisiae) DNA binding proteins by pairing ... microarrays. This set delivers robust hybridization ... true binding events and fewer false ...
... White solid.. PACKAGED UNDER INERT GAS. Cyclizes as ... "driven" to completion. A protective agent for SH ... many other preparations. Blocks the lethal and hypnotic ... Contaminants: Heavy metals: ≤1 ppm. ...
... to help promote genomics-based research with S. aureus, ... that contains PCR primers to amplify all open ... addition, primer pairs are included to amplify ORFs ... N315 strains of S. aureus. The ORFmer set ...
Biology Products: